http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2759277-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2015-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3880512bba4b1bce21e08e5392b10d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24c90e6a34424379c44e84bceac5c276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef78ab61e2a7f51f5ac1f77a4abb6765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67552b7b38aea238f899d93ce62fa988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cff02795fef056fe3196a382f3fdae3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dc7bffbcf14d6296df4774fad01e3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76b6e883ff0b681268e5f1d68c2d72a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93dfa38f7e0ba0567a180cf203c5e201 |
| publicationDate | 2020-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2759277-T3 |
| titleOfInvention | Chromen and 1,1a, 2,7b-tetrahydrocyclopropa [c] chromen pyridopirationiniones as gamma-secretase modulators |
| abstract | A compound having the structure of Formula I: ** Formula ** or a pharmaceutically acceptable salt thereof, wherein: A is selected from the group consisting of A1a, A1b and A3a: ** Formula ** or X is a heteroaryl (5 members) in which the heteroaryl is imidazolyl; R1 is a (C1-C6) alkyl, in which the alkyl is methyl; R2a, R2b, R4 a, R4b, R5a and R5b are each independently: i) hydrogen; or ii) (C1-C6) alkyl, in which (C1-C6) alkyl is methyl; R6 and R7 are each independently hydrogen; z and y are each 1; ring B is optionally substituted with up to three R10s, where each R10 is independently selected from halogen or (C1-C6) alkyl; ring C is optionally substituted with up to three R11 such that the substitution occurs at any carbon atom that is chemically permissible, and where each R11 is independently selected from halogen, (C1-C6) alkyl, or halo (C1-C6) alkyl. ); or two R11 taken together with the carbon atoms to which they are attached form a cycloalkyl (C3-C6) or a heterocycloalkyl (4 to 6 members), in which the cycloalkyl (C3-C6) and heterocycloalkyl (4 to 6 members) residues members) are each optionally substituted with one to three substituents independently selected from halogen or (C1-C6) alkyl; and Ring D is optionally substituted with up to three R12s, wherein each R12 is independently selected from the group consisting of halogen, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, haloalkoxy (C1-C6), - SF5 and (C3-C6) cycloalkyl, wherein the (C3-C6) cycloalkyl is optionally substituted with one to three substituents independently selected from halogen, (C1-C6 alkyl) or halo (C1- C6). |
| priorityDate | 2014-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1526.